Pharmaceutical Investing Zynerba Pharmaceuticals Reports First Quarter 2018 Financial Results and Operational Highlights
Pharmaceutical Investing Zynerba Pharmaceuticals Initiates Open-Label Phase 2 Trial of ZYN002 in Developmental and Epileptic Encephalopathies
Walker Lane Resources: Advancing High-grade Gold, Silver assets in North America’s Prolific Regions
Cartier Resources Closes Offering with Paradigm Capital and Concurrent Offering for Aggregate Gross Proceeds of $11,398,596
